Posts Tagged ‘drug dosing’

Neglect is a strong word. But if we want to be honest about the excessive emphasis on weight loss in obesity care, it seems appropriate. Research on new therapies for obesity have long neglected the challenge of maintenance therapy for this chronic disease. A new study in Obesity makes this gap plain to see. A […]

Yesterday, Amgen released topline data on their remarkable monthly obesity medicine – MariTide or maridebart cafraglutide. To us, the results are impressive, albeit preliminary. In 52 weeks of study, patients with obesity or overweight lost approximately 20% of their initial body weight and even after a year, they appeared to still be losing weight. For […]

Barely seven months ago, business reporters were telling us Pfizer had decided to “drop,” “stop,” “can,” or “pull the plug” on danuglipron – an oral small molecule for obesity. But as we pointed out at the time, they missed the real story. Pfizer was shifting its gears to focus on a once daily form of […]

At a hearing this week fo the U.S. House Committee on Energy and Commerce, Representative Robin Kelly asked the Director of the FDA Center for Drug Evaluation and Research, Patrizia Cavazzoni, what the agency is doing to ensure that drug labeling adequately protects the safety of people with obesity: “Patients with obesity are frequently excluded […]

A pair of studies with semaglutide at ECO2024 in Venice goes straight to the heart of some core questions about advanced obesity medicines. Does everyone need the full, maximum dose to get good results? Will everyone have to keep taking that full dose to keep obesity under control? The answer to both questions is no. […]

Perhaps the most persistent fault that people find with new obesity medicines is the need to keep taking them forever. “Nobody is ready ” for that, says Business Insider. “Patients hate forever drugs,” says the New York Times. And they have a point. Obesity medicine doctors are quick to say “suck it up.” That’s just […]

We learned recently that questions about the need for ongoing dosing with obesity medicines raise discomforting thoughts. After all, obesity is a chronic disease, so we can’t dispute the need for continued daily or weekly doses with obesity medicines. Or can we? Amgen seems to think we can. Monthly Dosing? Induction and Maintenance? With a […]

It is time to translate words into action and fix the blind spot in drug trials and labeling for people with obesity. Every major obesity group in the U.S. issued this united call to action on Tuesday. This includes the ASMBS, Obesity Action Coalition, Obesity Medicine, Obesity Society, and STOP Obesity Alliance. It comes as […]

Public health experts have long been accounting for it. People are living in larger bodies. Better than 40% of U.S. adults have a body weight in the range of obesity. But new reporting from JoNel Aleccia for the Associated Press tells us that pharma and the FDA are not yet accounting for this fact. It’s […]

It’s a “deficit of information” we should correct, says FDA Commissioner Robert Califf. He is speaking about the gap in information about how to correctly dose drugs for people living with obesity. Karen Weintraub, reporting for USA Today, tells us this gap might mean that doctors are prescribing the right drug at the wrong dose […]